Laryngeal pharyngeal squamous cell carcinomas
Conditions
Interventions
Trial group:Nituzumab concurrent chemoradiotherapy
Sponsors
Harbin Medical University Affiliated Tumor Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Pathologic squamous cell carcinoma stage III/IV head and neck carcinoma; 2. Aged 18 -70 years; 3. KPS score 70 or higher.
Exclusion criteria
Exclusion criteria: (1) Participated in other interventional clinical trials within 30 days prior to screening; (2) Patients with distant metastasis; (3) A history of other malignancies (except cured carcinoma in situ of the cervix or basal cell carcinoma of the skin and other malignancies that have been cured for more than 5 years); (4) Known to be infected with HIV or active viral hepatitis; (5) People who are allergic to drugs or other ingredients used in this program; (6) The researcher considers it inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 years total survival (OS) rate;2 year progression-free survival (PFS) rate;Objective remission rate (ORR);Median totale survival(OS);Medina progression-free survival (PFS);Quality of Life; | — |
Countries
China
Contacts
Public ContactHao Chuncheng
Harbin Medical University Affiliated Tumor Hospital
Outcome results
None listed